Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694103 | 0.94 | L3MBTL1 (0.39) | L3MBTL1LMNAMAPTRECQLSIGMAR1 | |
| SCHEMBL4693276 | 0.86 | LMNA (0.35) | L3MBTL1LMNAMAPTRECQLSIGMAR1 | |
| SCHEMBL4692952 | 0.85 | KDM1A (0.38) | LMNAMAPTSIGMAR1KMT2AMEN1 | |
| SCHEMBL4695303 | 0.84 | L3MBTL1 (0.40) | L3MBTL1LMNAMAPTRECQLSIGMAR1 | |
| SCHEMBL4696480 | 0.81 | BCHE (0.32) | KMT2ABCHEKDM1A | |
| SCHEMBL4694468 | 0.79 | CYP2D6 (0.40) | LMNAMAPTSIGMAR1KMT2AMEN1 | |
| SCHEMBL4694068 | 0.78 | L3MBTL1 (0.39) | L3MBTL1LMNAMAPTRECQLSIGMAR1 | |
| SCHEMBL4693840 | 0.78 | POLB (0.54) | L3MBTL1LMNAMAPTRECQLKMT2A | |
| SCHEMBL3883599 | 0.76 | SIGMAR1 (0.34) | LMNAMAPTSIGMAR1KMT2AHTR6 | |
| SCHEMBL4695790 | 0.76 | MEN1 (0.32) | LMNAMAPTSIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509528-B1 | 1,3-DIAZA-DIBENZOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | GLAXOSMITHKLINE ZAGREB (HR) | 2008-09-24 | — | — | EP | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | claimed |
| US-7166583-B2 | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-01-23 | — | — | US | claimed |
| EP-1684749-B1 | USE OF 1,3-DIAZA-DIBENZO[e,h] AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ZAGREB (HR) | 2007-09-05 | — | — | EP | disclosed |
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129330-A1 | 1,3-Diaza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders | DBH, BCHE, DDT | L3MBTL1 1797/4885LMNA 1828/4885MAPT 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.